Company news: Celgene

Share this article:
The FDA expanded the indication for Celgene's drug Abraxane Friday when it approved the injection for use as a first-line treatment for advanced non-small cell lung cancer. The FDA first approved Abraxane for treatment of metastatic breast cancer in 2005 among patients for whom combination chemotherapy did not work. Reuters noted that the drug maker is also seeking additional indications, including pancreatic and skin cancers. Reuters said a Barclays analyst projected that Abraxane could have peak annual lung cancer sales of $110 million.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.